JP2008500356A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500356A5
JP2008500356A5 JP2007515279A JP2007515279A JP2008500356A5 JP 2008500356 A5 JP2008500356 A5 JP 2008500356A5 JP 2007515279 A JP2007515279 A JP 2007515279A JP 2007515279 A JP2007515279 A JP 2007515279A JP 2008500356 A5 JP2008500356 A5 JP 2008500356A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
topical composition
independently hydrogen
receptor agonist
adrenergic receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515279A
Other languages
English (en)
Japanese (ja)
Other versions
JP4955543B2 (ja
JP2008500356A (ja
Filing date
Publication date
Priority claimed from US10/853,585 external-priority patent/US7439241B2/en
Application filed filed Critical
Priority claimed from PCT/US2005/018288 external-priority patent/WO2005115395A2/en
Publication of JP2008500356A publication Critical patent/JP2008500356A/ja
Publication of JP2008500356A5 publication Critical patent/JP2008500356A5/ja
Application granted granted Critical
Publication of JP4955543B2 publication Critical patent/JP4955543B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515279A 2004-05-25 2005-05-25 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法 Expired - Fee Related JP4955543B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57414204P 2004-05-25 2004-05-25
US10/853,585 US7439241B2 (en) 2003-05-27 2004-05-25 Compounds, formulations, and methods for treating or preventing rosacea
US60/574,142 2004-05-25
US10/853,585 2004-05-25
PCT/US2005/018288 WO2005115395A2 (en) 2004-05-25 2005-05-25 Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011263425A Division JP5547705B2 (ja) 2004-05-25 2011-12-01 紅斑を治療又は予防するための組成物

Publications (3)

Publication Number Publication Date
JP2008500356A JP2008500356A (ja) 2008-01-10
JP2008500356A5 true JP2008500356A5 (enExample) 2008-03-27
JP4955543B2 JP4955543B2 (ja) 2012-06-20

Family

ID=35451386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515279A Expired - Fee Related JP4955543B2 (ja) 2004-05-25 2005-05-25 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
JP2011263425A Expired - Fee Related JP5547705B2 (ja) 2004-05-25 2011-12-01 紅斑を治療又は予防するための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011263425A Expired - Fee Related JP5547705B2 (ja) 2004-05-25 2011-12-01 紅斑を治療又は予防するための組成物

Country Status (15)

Country Link
EP (2) EP1761266B1 (enExample)
JP (2) JP4955543B2 (enExample)
KR (1) KR101257046B1 (enExample)
CN (2) CN104490884A (enExample)
AU (1) AU2005247467B2 (enExample)
BR (1) BRPI0511519A (enExample)
CA (2) CA2824612C (enExample)
DK (1) DK1761266T3 (enExample)
ES (2) ES2647618T3 (enExample)
MX (1) MXPA06013649A (enExample)
NZ (1) NZ552325A (enExample)
PL (1) PL1761266T3 (enExample)
PT (1) PT1761266E (enExample)
SI (1) SI1761266T1 (enExample)
WO (1) WO2005115395A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
GB0611241D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
BR112012009891A2 (pt) * 2009-10-26 2015-09-29 Galderma Pharma Sa métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
CN106038476B (zh) 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
EP2629757A2 (en) * 2010-10-21 2013-08-28 Galderma S.A. Brimonidine gel compositions and methods of use
PH12013500679A1 (en) * 2010-10-21 2013-06-10 Galderma Sa Topical gel composition
CN101972272B (zh) * 2010-10-31 2012-07-04 无锡龙腾画材有限公司 一种二氧化氯皮肤凝胶及其制备方法
CA2818144C (en) * 2010-11-16 2020-09-22 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
JP6225030B2 (ja) * 2011-02-15 2017-11-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 酒さの症状を治療するためのオキシメタゾリンの薬学的クリーム組成物
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
EP2768502A2 (en) * 2011-10-19 2014-08-27 Galderma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
CA2911472A1 (en) * 2013-05-06 2014-11-13 Allergan, Inc. Alpha adrenergic agonists for the treatment of tissue trauma
JP2016525553A (ja) * 2013-07-26 2016-08-25 ガルデルマ・リサーチ・アンド・デヴェロップメント 皮膚肥厚の治療法
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US9937117B2 (en) * 2015-07-09 2018-04-10 Galderma S.A. Method of reducing hair loss associated with chemotherapy
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CN106727462B (zh) * 2016-11-14 2019-04-09 四川省人民医院 一种治疗面部皮炎的药物及其应用
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
WO2020232020A1 (en) * 2019-05-14 2020-11-19 Abend Fritz Ventures Llc Compositions and methods for removal of skin adhesive patches, products, and residual adhesives
KR20230058444A (ko) * 2020-08-26 2023-05-03 오티카라 인코포레이티드 코, 귀 및 다른 조직 감염 및/또는 염증을 치료하기 위한 조성물, 디바이스 및 방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
IT1252692B (it) * 1991-11-27 1995-06-23 Zambon Spa Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
JPH1129482A (ja) * 1997-05-14 1999-02-02 Taisho Pharmaceut Co Ltd 医薬組成物
CA2311344C (en) * 1997-11-24 2006-02-07 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
IN185228B (enExample) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
IL151530A0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP3520076B2 (ja) * 2001-10-02 2004-04-19 憲司 中村 皮膚外用剤
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists

Similar Documents

Publication Publication Date Title
JP2008500356A5 (enExample)
CA2530938A1 (en) Compounds, formulations, and methods for treating or preventing rosacea
RU2538729C2 (ru) Применение агонистов альфа 2 адренергических рецепторов для лечения или предотвращения псориаза
CA2567401C (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
JP6185536B2 (ja) ブリモニジンゲル組成物及び使用方法
KR20120125230A (ko) 급성 홍반 치료 또는 예방 방법
JP2013511534A5 (enExample)
RU2012124904A (ru) КОМБИНАЦИЯ АГОНИСТА α2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ И НЕСТЕРОИДНОГО ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ВОСПАЛИТЕЛЬНОГО ПОРАЖЕНИЯ КОЖИ
JP2013540142A (ja) 局所ゲル組成物
CN106535936A (zh) 治疗手足综合征及与其相关的症状的方法
US20200222396A1 (en) Methods and compositions for reducing side effects in chemotherapeutic treatments
HK1174537A (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
HK1084591B (en) Compounds, formulations, and methods for treating or preventing rosacea